0001104659-20-042771.txt : 20200403 0001104659-20-042771.hdr.sgml : 20200403 20200403090218 ACCESSION NUMBER: 0001104659-20-042771 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200402 FILED AS OF DATE: 20200403 DATE AS OF CHANGE: 20200403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ricardo Alonso CENTRAL INDEX KEY: 0001768722 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37926 FILM NUMBER: 20771817 MAIL ADDRESS: STREET 1: C/O RA PHARMACEUTICALS, INC. STREET 2: 87 CAMBRIDGEPARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001481512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262908274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 87 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617) 401-4060 MAIL ADDRESS: STREET 1: 87 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 4 1 a4.xml 4 X0306 4 2020-04-02 1 0001481512 Ra Pharmaceuticals, Inc. RARX 0001768722 Ricardo Alonso C/O RA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 0 1 0 0 See Remarks Common Stock 2020-04-02 4 D 0 2973 48.00 D 0 D Stock Option (Right to Buy) 0.84 2020-04-02 4 D 0 2857 0 D 2022-06-14 Common Stock 2857 0 D Stock Option (Right to Buy) 2.87 2020-04-02 4 D 0 14285 0 D 2024-12-11 Common Stock 14285 0 D Stock Option (Right to Buy) 2.87 2020-04-02 4 D 0 30000 0 D 2025-12-10 Common Stock 30000 0 D Stock Option (Right to Buy) 5.60 2020-04-02 4 D 0 31428 0 D 2026-08-16 Common Stock 31428 0 D Stock Option (Right to Buy) 16.64 2020-04-02 4 D 0 60000 0 D 2027-02-01 Common Stock 60000 0 D Stock Option (Right to Buy) 7.33 2020-04-02 4 D 0 26250 0 D 2028-02-01 Common Stock 26250 0 D Stock Option (Right to Buy) 21.00 2020-04-02 4 D 0 107000 0 D 2029-02-01 Common Stock 107000 0 D Restricted Stock Units 2020-04-02 4 D 0 4375 0 D Common Stock 4375 0 D Includes 2,973 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020. Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. The Reporting Person is Chief Technology and Innovation Officer and Head of Research. /s/ David C. Lubner, Attorney-in Fact for Alonso Ricardo 2020-04-03